These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19952538)

  • 1. [Proposal of a novel dosing schedule of docetaxel by using alpha1-acid glycoprotein as an index].
    Ozawa K; Minami H; Sato H
    Yakugaku Zasshi; 2009 Dec; 129(12):1565-72. PubMed ID: 19952538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
    Ozawa K; Minami H; Sato H
    Yakugaku Zasshi; 2009 Jun; 129(6):749-57. PubMed ID: 19483418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose schedule optimization and the pharmacokinetic driver of neutropenia.
    Patel M; Palani S; Chakravarty A; Yang J; Shyu WC; Mettetal JT
    PLoS One; 2014; 9(10):e109892. PubMed ID: 25360756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.
    Ozawa K; Minami H; Sato H
    Cancer Sci; 2007 Dec; 98(12):1985-92. PubMed ID: 17888031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
    Netterberg I; Nielsen EI; Friberg LE; Karlsson MO
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):343-353. PubMed ID: 28656382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
    Yamamoto N; Tamura T; Murakami H; Shimoyama T; Nokihara H; Ueda Y; Sekine I; Kunitoh H; Ohe Y; Kodama T; Shimizu M; Nishio K; Ishizuka N; Saijo N
    J Clin Oncol; 2005 Feb; 23(6):1061-9. PubMed ID: 15657405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of advanced age and serum α
    Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
    Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
    Nieuweboer AJ; Smid M; de Graan AM; Elbouazzaoui S; de Bruijn P; Eskens FA; Hamberg P; Martens JW; Sparreboom A; de Wit R; van Schaik RH; Mathijssen RH
    Pharmacogenomics J; 2016 Nov; 16(6):519-524. PubMed ID: 26345519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.
    Meille C; Iliadis A; Barbolosi D; Frances N; Freyer G
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):619-33. PubMed ID: 19107581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
    Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models.
    Chen W; Chen R; Li J; Fu Y; Yang L; Su H; Yao Y; Li L; Zhou T; Lu W
    J Pharmacol Exp Ther; 2018 Jan; 364(1):13-25. PubMed ID: 29084815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical aspects of weekly docetaxel administration schedules.
    Hainsworth JD
    Oncologist; 2004; 9(5):538-45. PubMed ID: 15477638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
    Kathman SJ; Williams DH; Hodge JP; Dar M
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.